Trial Profile
A two-year, multicenter, double-blind, randomized, placebo-controlled and parallel group study of oral risedronate 5 mg daily in the prevention of osteoporosis in osteopenic postmenopausal women (more than 5 years postmenopausal)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Jan 2010
Price :
$35
*
At a glance
- Drugs Risedronic acid (Primary)
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Sanofi
- 07 Jul 2009 Actual end date (Apr 2005) added as reported by ClinicalTrials.gov.
- 19 Sep 2006 New trial record.